OPDIVO (nivolumab), anti-PD-1 antibody

ONCOLOGY - New medicinal product

Opinions on drugs - Posted on Jun 17 2016

Inclusion

Moderate clinical added value in first-line treatment of advanced melanoma.

OPDIVO has marketing authorisation as monotherapy in the treatment of adults with advanced (unresectable or metastatic) melanoma.
In the absence of BRAF mutation, like pembrolizumab (KEYTRUDA), it is recommended as first-line treatment.
If there is BRAF mutation, like pembrolizumab (KEYTRUDA), its role as an alternative to targeted therapies is currently debated, especially the patient profile that could receive one of these two treatments as a first line.

Substantial

moderate

Therapeutic use

Évaluation des médicaments

My account